share_log

Guiyang Xintian PharmaceuticalLtd's (SZSE:002873) Problems Go Beyond Weak Profit

Guiyang Xintian PharmaceuticalLtd's (SZSE:002873) Problems Go Beyond Weak Profit

贵阳新天制药有限公司(深圳证券交易所:002873)的问题不仅仅是利润疲软
Simply Wall St ·  05/08 18:39

Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) stock showed strength, with investors undeterred by its weak earnings report. We think that shareholders might be missing some concerning factors that our analysis found.

贵阳新天药业有限公司, Ltd. 's(SZSE:002873)股票表现强劲,投资者并未被其疲软的收益报告所吓倒。我们认为,股东可能遗漏了我们的分析发现的一些相关因素。

earnings-and-revenue-history
SZSE:002873 Earnings and Revenue History May 8th 2024
SZSE: 002873 收益和收入历史记录 2024 年 5 月 8 日

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

For anyone who wants to understand Guiyang Xintian PharmaceuticalLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥7.1m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. If Guiyang Xintian PharmaceuticalLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

对于任何想了解贵阳新天制药有限公司在法定数字之外的利润的人来说,值得注意的是,在过去的十二个月中,从价值710万元人民币的不寻常物品中获得了法定利润。我们不能否认更高的利润通常会让我们感到乐观,但如果利润是可持续的,我们更愿意这样做。当我们计算数千家上市公司的数字时,我们发现,特定年份中不寻常的项目所带来的提振通常不会在第二年重演。这正如你所预料的那样,因为这些增强被描述为 “不寻常”。如果贵阳新天制药有限公司的捐款不会重演,那么在其他条件相同的情况下,我们预计其本年度的利润将下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

Our Take On Guiyang Xintian PharmaceuticalLtd's Profit Performance

我们对贵阳新天制药有限公司盈利表现的看法

Arguably, Guiyang Xintian PharmaceuticalLtd's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Guiyang Xintian PharmaceuticalLtd's statutory profits are better than its underlying earnings power. In further bad news, its earnings per share decreased in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. You'd be interested to know, that we found 1 warning sign for Guiyang Xintian PharmaceuticalLtd and you'll want to know about this.

可以说,贵阳新天制药有限公司的法定收益被提高利润的不寻常项目所扭曲。正因为如此,我们认为贵阳新天制药有限公司的法定利润可能好于其基础盈利能力。另一个坏消息是,其每股收益在去年有所下降。归根结底,如果你想正确地了解公司,必须考虑的不仅仅是上述因素。有鉴于此,如果你想对公司进行更多分析,了解所涉及的风险至关重要。你可能会有兴趣知道,我们找到了贵阳新天制药有限公司的1个警告标志,你会想知道的。

This note has only looked at a single factor that sheds light on the nature of Guiyang Xintian PharmaceuticalLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

这份报告只研究了揭示贵阳新天制药有限公司利润性质的单一因素。但是,还有很多其他方法可以让你对公司的看法。有些人认为高股本回报率是优质业务的好兆头。因此,你可能希望看到这份免费收藏的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发